<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760786</url>
  </required_header>
  <id_info>
    <org_study_id>SMC IRB 2007-09-006</org_study_id>
    <nct_id>NCT00760786</nct_id>
  </id_info>
  <brief_title>Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque</brief_title>
  <official_title>Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque: Serial Virtual Histology Intravascular Ultrasound Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intensive lipid lowering and Omega-3 fatty
      acid are effective in the treatment of coronary atherosclerotic plaque.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plaque stabilization using serial virtual histology intravascular ultrasound analysis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensive lipid lowering plus Omega3-fatty acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate lipid lowering plus Omega3-fatty acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intensive lipid lowering plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moderate lipid lowering plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive lipid lowering plus Omega3-fatty acid</intervention_name>
    <description>Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate lipid lowering plus Omega3-fatty acid</intervention_name>
    <description>atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive lipid lowering plus placebo</intervention_name>
    <description>atorvastatin 40mg qd</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate lipid lowering plus placebo</intervention_name>
    <description>atorvastatin 10mg qd</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome within 48 hours of symptom onset

          -  Have de novo non-culprit coronary artery stenosis 20% to 70% by visual estimation

        Exclusion Criteria:

          -  Cardiogenic shock

          -  ST segment elevation myocardial infarction within 1 week

          -  Hematologic disorder: neutropenia (neutrophil&lt;3000/mm3), thrombocytopenia
             (platelet&lt;100,000/mm3)

          -  Liver enzyme elevation: serum aspartate aminotransferase or alanine aminotransferase
             concentrations more than 3 times the upper limit of normal

          -  Impaired renal function with serum creatinine &gt; 2mg/dL

          -  Bleeding diathesis or history of coagulopathy

          -  Pregnancy

          -  Hypersensitivity to heparin, dye, aspirin, clopidogrel, statin, or fish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Yong Han, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyeon-Cheol Gwon, Professor</last_name>
    <phone>82-2-3410-3419</phone>
    <email>hc.gwon@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiac and Vascular Center; Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon-Cheol Gwon, Professor</last_name>
      <phone>82234103419</phone>
      <email>hc.gwon@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Joo-Yong Hahn, MD, PhD / Professor</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>IVUS-VH</keyword>
  <keyword>Plaque characterization</keyword>
  <keyword>Omega3-fatty acid</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

